The advent of molecular targeted therapies, particularly those targeting receptor tyrosine kinases in advanced NSCLC (e.g., mutations in the epidermal growth factor receptor [EGFR] or anaplastic lymphoma kinase [ALK] genes), has revolutionized lung cancer treatment. Here, ALK is linked to lung carcinoma.